A medication commonly used to treat type 2 diabetes and promote weight loss may have an unexpected benefit: repairing damage caused by osteoarthritis. Recent research suggests the active ingredient semaglutide could protect and even restore tissues affected by the condition, the most prevalent form of arthritis worldwide.
The research, conducted by a team of specialists from China and the United States and published in the scientific journal Cell Metabolism, indicates the drug may directly influence the metabolism of cartilage cells, rather than simply reducing pressure on joints through weight loss.
More Than Just Weight Loss
Semaglutide is the active substance in medications Ozempic and Wegovy. These drugs mimic the action of a natural hormone called GLP-1 (glucagon-like peptide‑1), which stimulates insulin release and helps control blood sugar. Simultaneously, the hormone signals the brain to feel full, leading to reduced appetite. This discovery is significant as osteoarthritis affects millions and current treatments primarily focus on managing symptoms rather than reversing damage.
Until now, the benefits of these medications for joints were thought to stem mainly from weight loss. A lower body weight means less pressure on the joints, particularly the knees and hips. Still, the new research suggests semaglutide may have a more profound effect, acting directly on the cells that produce and maintain healthy cartilage.
“This study highlights the potential of semaglutide as a treatment for metabolic osteoarthritis and shows that there is a repair mechanism independent of weight loss,” the authors noted, according to Science Alert.
Promising Results in Both Animal and Human Studies
In experiments conducted on mice, researchers observed that semaglutide alters how cartilage cells, called chondrocytes, function. Essentially, the drug “reprograms” their metabolism, allowing them to produce more energy and better survive the conditions created by osteoarthritis.
To determine if the effects observed in animals could also be seen in humans, researchers conducted a small clinical study. Twenty participants, aged 50 to 75, who were both obese and had osteoarthritis were randomly divided into two groups.
One group received treatment with sodium hyaluronate – a form of hyaluronic acid used to lubricate joints. The other group received the same therapy, but in combination with semaglutide.
After 24 weeks, patients who received semaglutide reported lower pain scores and significant improvements in knee function. MRI scans showed thicker cartilage and signs of regeneration in areas of the joint that bear the body’s weight.
The discovery adds to a growing number of studies suggesting that GLP-1 based medications may have medical benefits beyond weight control and blood sugar management.
However, researchers caution that the results should be interpreted with prudence. Animal studies do not always translate into long-term benefits for humans, and semaglutide itself has side effects and limitations.
Osteoarthritis is the most common form of arthritis, affecting approximately 600 million people globally. Experts estimate that by 2050, the number of affected individuals could reach one billion.
The disease is becoming increasingly common among the active and relatively young population, which can signify decades of pain and functional limitations.
Currently, most available treatments are primarily palliative: they reduce pain and inflammation, but fail to stop or reverse cartilage degradation.
